CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,914,570 | -8.8% | 240,462 | +12.9% | 0.01% | -7.1% |
| Q2 2023 | $11,962,031 | +25.9% | 213,075 | +1.5% | 0.01% | +27.3% |
| Q1 2023 | $9,498,571 | +28.5% | 210,006 | +15.5% | 0.01% | +22.2% |
| Q4 2022 | $7,391,268 | -0.6% | 181,827 | +57.7% | 0.01% | 0.0% |
| Q3 2022 | $7,435,000 | +18.0% | 115,291 | +11.2% | 0.01% | +28.6% |
| Q2 2022 | $6,299,000 | +213.4% | 103,661 | +223.7% | 0.01% | +250.0% |
| Q1 2022 | $2,010,000 | -22.6% | 32,025 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $2,597,000 | -23.7% | 34,273 | +12.8% | 0.00% | -50.0% |
| Q3 2021 | $3,402,000 | -7.5% | 30,397 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $3,679,000 | -3.8% | 30,397 | -3.2% | 0.00% | 0.0% |
| Q1 2021 | $3,826,000 | -21.2% | 31,396 | -1.0% | 0.00% | -33.3% |
| Q4 2020 | $4,855,000 | – | 31,708 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |